A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Trial Profile

A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs ARGX 110 (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions
  • Sponsors argenx
  • Most Recent Events

    • 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 May 2016 New trial record
    • 03 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top